Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC-2 trial of nivolumab after immune induction in metastatic triple-negative breast cancer
NL-OMON58669Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in triple-negative breast cancer (TNBC) (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival after 6 cycles of nivolumab (PFS1). Started Feb 2020; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON58669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58669.